📊 ZLAB Key Takeaways
Is Zai Lab Ltd (ZLAB) a Good Investment?
Zai Lab is burning cash (-$13.1M FCF annually) while generating negligible revenue growth (0.7% YoY), with severe operating losses (-69.7% margin) indicating fundamental commercialization challenges. Although the $651.3M cash position and improving loss trends provide some runway, the stalled revenue base and unsustainable cash burn present material risk without demonstrated acceleration.
Zai Lab Ltd Key Strengths (ZLAB)
- Strong cash position of $651.3M with zero long-term debt provides extended runway
- Improving loss trends year-over-year (net loss improved 31.7%) shows operational progress
- Solid balance sheet with positive $662M equity and 2.40x current ratio limits liquidity risk
ZLAB Stock Risks: Zai Lab Ltd Investment Risks
- Negative free cash flow of -$13.1M with essentially flat revenue growth (0.7%) demonstrates unsustainable unit economics
- Severe operating losses of -$69.4M on $99.6M revenue (-69.7% margin) with no clear profitability timeline
- Stalled revenue growth and negative operating cash flow suggest pipeline commercialization failures or market adoption challenges
Key Metrics to Watch
- Operating cash flow trajectory toward breakeven and cash burn rate
- Revenue growth acceleration and pipeline commercialization success rates
- Operating margin improvement toward profitability with revenue scaling
Zai Lab Ltd (ZLAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.40x current ratio provides a solid financial cushion.
ZLAB Profit Margin, ROE & Profitability Analysis
ZLAB vs Healthcare Sector: How Zai Lab Ltd Compares
How Zai Lab Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zai Lab Ltd Stock Overvalued? ZLAB Valuation Analysis 2026
Based on fundamental analysis, Zai Lab Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zai Lab Ltd Balance Sheet: ZLAB Debt, Cash & Liquidity
ZLAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zai Lab Ltd's revenue has grown significantly by 217% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.35 indicates the company is currently unprofitable.
ZLAB Revenue Growth, EPS Growth & YoY Performance
ZLAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $95.6M | -$48.4M | $-0.04 |
| Q3 2025 | $101.8M | -$36.0M | $-0.03 |
| Q2 2025 | $100.1M | -$40.7M | $-0.04 |
| Q1 2025 | $87.1M | -$48.4M | $-0.04 |
| Q3 2024 | $69.2M | -$41.7M | $-0.04 |
| Q2 2024 | $68.9M | -$49.1M | $-0.08 |
| Q1 2024 | $62.8M | -$49.1M | $-0.05 |
| Q3 2023 | $57.0M | -$49.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zai Lab Ltd Dividends, Buybacks & Capital Allocation
ZLAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zai Lab Ltd (CIK: 0001704292)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZLAB
What is the AI rating for ZLAB?
Zai Lab Ltd (ZLAB) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZLAB's key strengths?
Claude: Strong cash position of $651.3M with zero long-term debt provides extended runway. Improving loss trends year-over-year (net loss improved 31.7%) shows operational progress.
What are the risks of investing in ZLAB?
Claude: Negative free cash flow of -$13.1M with essentially flat revenue growth (0.7%) demonstrates unsustainable unit economics. Severe operating losses of -$69.4M on $99.6M revenue (-69.7% margin) with no clear profitability timeline.
What is ZLAB's revenue and growth?
Zai Lab Ltd reported revenue of $99.6M.
Does ZLAB pay dividends?
Zai Lab Ltd does not currently pay dividends.
Where can I find ZLAB SEC filings?
Official SEC filings for Zai Lab Ltd (CIK: 0001704292) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZLAB's EPS?
Zai Lab Ltd has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZLAB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zai Lab Ltd has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZLAB stock overvalued or undervalued?
Valuation metrics for ZLAB: ROE of -7.7% (sector avg: 15%), net margin of -51.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZLAB's AI grade for 2026?
Our dual AI analysis gives Zai Lab Ltd a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZLAB's free cash flow?
Zai Lab Ltd's operating cash flow is $-11.9M, with capital expenditures of $1.2M. FCF margin is -13.2%.
How does ZLAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -51.2% (avg: 12%), ROE -7.7% (avg: 15%), current ratio 2.40 (avg: 2).